Bharat Biotech ramping up manufacturing capacity to 70 Cr doses: Dr. Raches Ella
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
As of 2nd May 2021, the Government has provided more 16.54 crore COVID-19 vaccine doses to States/UTs free of cost
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Subscribe To Our Newsletter & Stay Updated